A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Sustainable Views, Financial Times: Healthcar...
Media - published on 07 Apr 2022
Share

Sustainable Views, Financial Times: Healthcare stewards see success on access to vaccines

The Access to Medicine Foundation's Director of Strategy, Damiano de Felice, spoke with Financial Times journalist Angus Peters for an article examining how the pandemic has brought the issue of global access into the mainstream for investors in pharmaceutical companies.

Explore further

Media

Responsible Investor reports on the AMR Benchmark

Responsible Investor ESG Briefing reports on the publication of the first-ever AMR Benchmark.
Feature

How we work with investors

Numerous investors already work with the Access to Medicine Foundation to improve their knowledge of how pharmaceutical companies manage risks and opportunities related to access-to-medicine and antimicrobial resistance (AMR). As of January 2021, 100+ investors – together managing assets of more than USD 18 trillion – have signed the Access to Medicine Index Investor Statement and committed to using the research of the Access to Medicine Foundation in their investment analysis and engagements with companies.
Media

Project Syndicate op-ed: Insulin Belongs to the World

In an op-ed published by Project Syndicate, Access to Medicine Foundation CEO Jayasree K. Iyer argues that governments and pharmaceutical companies must do their part to increase access to insulin in low- and middle-income countries – including not just older forms of human insulin, but also the innovative analog insulins which are increasingly becoming the preferred choice of both diabetes patients and doctors.

Get in touch

Back to top |